Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

OTC Markets Group Welcomes Theralase Technologies Inc. to OTCQX

PR Newswire June 2, 2017

Theralase Commences Trading on OTCQX

Filing Services Canada June 2, 2017

Theralase Increases Revenue 23% for 1Q2017 Financial Statements

Filing Services Canada May 30, 2017

Theralase says objectives for anti-cancer treatment have been met

Stockhouse Editorial May 26, 2017

Theralase Successfully Achieves Primary and Secondary Objectives for First Three Patients Treated Using Anti-Cancer Technology for Bladder Cancer

Filing Services Canada May 26, 2017

Theralase Reports Fiscal Year 2016 Financial Statements

Filing Services Canada May 1, 2017

Theralase PDT Technology Used to Treat Third Patient for Bladder Cancer

Filing Services Canada April 20, 2017

Theralase PDT Technology Used to Treat Second Patient for Bladder Cancer

Filing Services Canada April 18, 2017

Theralase Grants Stock Options

Filing Services Canada April 18, 2017

Is a Trojan Horse the Key to Curing Cancer?

Jeff Nielson April 13, 2017

Theralase Affiliated Researchers to Present at International Conference

Filing Services Canada April 12, 2017

New Class of Compounds May Be Effective In Cancer Fight

Stockhouse Editorial April 7, 2017

Theralase Announces Acceptance of Peer Reviewed Publication for Next Generation Anti-Cancer Drugs

Filing Services Canada April 6, 2017

Theralase PDT Technology Used to Treat First Patient for Bladder Cancer

Filing Services Canada April 4, 2017

Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug

Filing Services Canada March 15, 2017

Theralase Releases AGM Presentation Video

Filing Services Canada December 14, 2016

Theralase Adopts Advance Notice By-Law

Filing Services Canada December 13, 2016

Theralase Commences Phase Ib Clinical Study

Filing Services Canada December 9, 2016

Theralase Demonstrates 12 Month Stability of Lead Anti-Cancer Drug

Filing Services Canada November 30, 2016

Theralase Increases Revenue 14% in 3Q2016

Filing Services Canada November 29, 2016